NAS:BBIO (USA) Also Trade In: Germany

BridgeBio Pharma Inc $ 69.48 3.04 (4.58%)

Volume:
587,481
Avg Vol (1m):
644,546
Market Cap $:
8.53 Bil
Enterprise Value $:
8.35 Bil
P/E (TTM):
0.00
P/B:
50.13
Warning! GuruFocus has detected 1 Severe warning sign with BBIO. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for BridgeBio Pharma Inc () from 2019 to Jan 24 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. BridgeBio Pharma stock (BBIO) PE ratio as of Jan 24 2021 is 0. More Details

BridgeBio Pharma PE Ratio (TTM) Chart

EMBED

BridgeBio Pharma PE Ratio (TTM) Historical Data

Total 413
  • 1
  • 2
  • 3
  • 4
  • 5
BridgeBio Pharma PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-01-240.0 2020-11-230.0
2021-01-220.0 2020-11-200.0
2021-01-210.0 2020-11-190.0
2021-01-200.0 2020-11-180.0
2021-01-190.0 2020-11-170.0
2021-01-180.0 2020-11-160.0
2021-01-150.0 2020-11-130.0
2021-01-140.0 2020-11-120.0
2021-01-130.0 2020-11-110.0
2021-01-120.0 2020-11-100.0
2021-01-110.0 2020-11-090.0
2021-01-080.0 2020-11-060.0
2021-01-070.0 2020-11-050.0
2021-01-060.0 2020-11-040.0
2021-01-050.0 2020-11-030.0
2021-01-040.0 2020-11-020.0
2021-01-010.0 2020-10-300.0
2020-12-310.0 2020-10-290.0
2020-12-300.0 2020-10-280.0
2020-12-290.0 2020-10-270.0
2020-12-280.0 2020-10-260.0
2020-12-250.0 2020-10-230.0
2020-12-240.0 2020-10-220.0
2020-12-230.0 2020-10-210.0
2020-12-220.0 2020-10-200.0
2020-12-210.0 2020-10-190.0
2020-12-180.0 2020-10-160.0
2020-12-170.0 2020-10-150.0
2020-12-160.0 2020-10-140.0
2020-12-150.0 2020-10-130.0
2020-12-140.0 2020-10-120.0
2020-12-110.0 2020-10-090.0
2020-12-100.0 2020-10-080.0
2020-12-090.0 2020-10-070.0
2020-12-080.0 2020-10-060.0
2020-12-070.0 2020-10-050.0
2020-12-040.0 2020-10-020.0
2020-12-030.0 2020-10-010.0
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0
2020-11-260.0 2020-09-240.0
2020-11-250.0 2020-09-230.0
2020-11-240.0 2020-09-220.0

BridgeBio Pharma PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834
Traded in other countries 2CL.Germany BBIO.USA
Address 421 Kipling Street, Palo Alto, CA, USA, 94301
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.